Indoco Remedies Limited — Updates, 13-08-2025: Press Release

Indoco Remedies secured final USFDA approval for Rivaroxaban Tablets USP, its generic equivalent to Janssen's Xarelto. This significant development enables Indoco to market the drug, used for treating venous thromboembolism, in the crucial US market. Management highlights this approval as a key driver for accelerating growth aspirations in the US. The company, with a turnover of US$ 180 million, sees this as a testament to its high-quality standards.